Gene therapy can be defined as the transfer of genetic material into a cell for therapeutic purposes. Cytosine deaminase (CD) transferred into tumor cells by an adenoviral vector (Ad.CD), can convert the antifungal drug fluorocytosine (5-FC) to the antimetabolite 5-fluorouracil (5-FU), which kills not only the transfected tumor cells but also their neighbors by the so-called 'bystander effect'. After testing a protocol for Ad.CD transfer and lung tumor burden control in a Lewis mouse model, we used this technique in the management of lung cancer patients with malignant pleural effusion (MPE): two cases are presented investigating the possible enhancement of anticancer effect in both non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) by local activation of the pro-drug 5-FC. Results were discussed in parallel to a literature review on the topic. 5-FC and Ad.CD were administered intratumorally to Lewis mouse lung carcinoma and the effect was monitored by tumor size and electromicroscopy. Two patients with advanced stage lung cancer (1SCLC, 1NSCLC), which developed MPE during first-line treatment were administered 10 12 plaque-forming unit (pfu) Ad.CD by intrapleural instillation, in two doses (day1 and day7). Instillation was performed when the pleural fluid was p200 ml. In addition, they received 5-FC 500 mg four times daily for 14 days. Lung tumor regression and successful transfer of adenoviral particles were observed in treated animals. Patients presented complete regression of pleural effusion as monitored by computerized tomography scan. Neutrapenia and anemia were the most severe adverse effect presented (grade III/grade IV 100%). The increased toxicity followed by the intrapleural gene therapy indicates the augmentation of anticancer effect of transformed pro-drug 5-FC to active 5-FU. The obtained data indicate that intrapleural gene therapy may be a useful tool, adjunct to chemotherapy, in the management of MPE related to lung cancer.
INTRODUCTION
Lung is the leading cancer site in males, comprising 17% of the total new cancer cases and 23% of the total cancer deaths. Cancer survival tends to be poorer in developing countries, most likely because of a combination of a late stage at diagnosis and limited access to timely and standard treatment.
Small-cell lung carcinomas (SCLC) represent 15--18% of all lung cancers with 10% 5-year survival rate, despite sensitivity to radiotherapy and chemotherapy. 1 Platinum analogs and etoposide-based chemotherapy combined with radiotherapy is the cornerstone treatment. Several combination first-line therapies, including topotecan or irrinotecan with or without bevasizumab, presented favorable data regarding progression-free survival and overall survival in extensive stage SCLC. However, the results were not statistical significantly improved in comparison to the already used doubled treatment. 2, 3 In addition, acquired resistance has been presented to chemotherapeutic agents used in SCLC. 4 Also, because of the high risk of brain metastases, prophylactic cranial irradiation is indicated in responders with limited disease and should be part of the standard management.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer worldwide and many clinical studies are currently assessing new chemotherapy combinations for this type of cancer. 5--7 Targeted therapies or even tailored according to tumor biomarker have been incorporated in lung cancer treatment; nevertheless, the overall survival failed to present the expected progression-free survival or overall survival. 8 Moreover, resistance of NSCLC cell lines to cytotoxic agents that mainly underlie the apoptotic mechanism have been observed. 9 Malignant pleural effusion (MPE) is commonly presented in lung cancer and is associated with advanced disease and short life expectancy. 10--12 Investigation of the molecular pathways of the MPE presented a strong association between angiogenesis and increased permeability of the existing and newly formed blood vessels. 13 However, limited studies reported management of the MPE.
Novel therapies for lung cancer are, therefore, in great demand.
14 Locoregional therapies have already been used in different types of cancer and suicide gene therapy constitutes a promising treatment strategy. 15--17 It is based on the introduction of a therapeutic gene encoding, enzyme capable of transforming a nontoxic pro-drug into a cell toxin. 15--17 Suicide gene therapy, utilizing the cytosine deaminase/5-fluorocytosine (CD/5-FC) system, represents an attractive methodology for targeted therapy in cancer research with favorable results in previously published studies. 18--21 As illustrated in Figure 1 , the CD enzyme converts the antifungal agent 5-FC into its antimetabolite 5-fluorouracil (5-FU), thereby killing tumor cells. Most suicide genes under investigation mediate sensitivity by encoding viral or bacterial enzymes that convert inactive forms of a drug into toxic metabolites capable of inhibiting nucleic acid synthesis. 22, 23 The bystander effect, through which the Ad.CD system applies, refers to the fact that the prodrug is activated into an antineoplastic agent in only a percentage of the target cells expressing the drug-activating enzyme. These cells are killed as a result of this expression, thus releasing the newly formed anticancer agent to the tumor microenvironment killing also adjacent cells. 22--31 Taken into consideration the above data, we firstly applied the method for Ad.CD transfer and lung tumor burden control in a Lewis lung cancer mouse model. Following results demonstrating successful adenoviral transfer in lung cancer cells and tumor regression, we evaluated the therapeutic efficacy of intrapleural Ad.CD administration in combination with 5-FC in two patients suffering from SCLC and NSCLC with MPE. Notably, patients receiving the intrapleural gene therapy presented complete regression of pleural effusion as a result to the augmentation of the anticancer effect of the transformed pro-drug 5-FC to active 5-FU.
MATERIALS AND METHODS

Recombinant adenovirus
The Ad.CD used in this study was kindly donated by Dr AB Deisseroth (Yale University School of Medicine, New Haven, US). This vector is a replicationincompetent recombinant adenoviral vector that contained the Escherichia coli CD gene in a L-plastine promoter-driven transcription unit 32 Ad.CD was propagated in 293 cells (ATCC, Teddington, UK) and recovered 36 h after infection by five cycles of freezing/thawing of the infected cells. All viral preparations were purified by CsCl density centrifugation, dialyzed and stored in dialysis buffer (10 mM Tris pH 7.8, 150 mM NaCL, 10 mM MgCl2 and 10% glycerol) at À70 1C before use. Titers of the viral stocks were determined by plaque assay using 293 cells by the standard methods. 33 Electro-microphotograph was used to observe the adenovirus particles in Lewis lung cancer cells, and pleural effusion smear. (Figures 2--4) .
Experimental mouse lung cancer model Male C57Bl/6 mice at 6--8 weeks old were obtained from the Theagen Anticancer Institute Research Laboratory, Thessaloniki, Greece. In total, 60 mice were included in the experiment (5 per cage) in a temperaturecontrolled room on 12-h light--dark cycle and were allowed free access to food and water. Lewis' lung cancer cell line was used for tumor implantation (2 Â 10 7 cells ml À1 ). The right hind leg was inoculated subcutaneously (27-guage needle) with 0.1 ml of cell suspension following local disinfection. The tumor volume was measured twice weekly using bidimensional diameters (caliper) with the equation V ¼ 1/2ab 2 , where a represents the largest diameter and b the smallest. The animals were randomly divided into three groups of 20, when the tumor volume reached B100 mm 3 . Group A was the negative control group (tumor without therapy). In group B, only 5-FC was administered intratumorally for 10 days D1--D10 (0.5 mg). In group C, 5-FC (0.5 mg) was similarly administered intratumorally for 10 days D1--D10 and 1 12 plaque-forming unit (pfu) Ad.CD on D2 (only once). The mice were killed on day 28 in all the groups, or before upon death. Lung carcinoma tissue was dissected Survival differences among the three groups were estimated with Kaplan--Meier survival analysis and with Breslow (Generalized Wilcoxon) test. Cox regression survival analysis was performed for all cases and for each group separately to compare volume with survival. Null hypothesis was rejected when Po0.005.
Patient enrollment and ethical policy
Patients were admitted in the Pulmonary Department-Oncology Unit, 'G. Papanikolaou' General Hospital, Aristotle University of Thessaloniki, Greece. Eligibility for the study was based on (a) pathologically confirmed diagnosis with SCLC and NSCLC, (b) performance status 0--1, (c) accessible pleural space for drug formulation instillation and (d) daily MPE production p200cc. Exclusion criteria were (a) previous pleurodesis attempt, (b) inadequate pulmonary function, (c) baseline pericardial effusion and (d) presence of cardiac, hepatic and renal failure. The patients included underwent insertion of a tunneled intrapleural catheter (24 CH) under local anesthesia with the guidance of a portable ultrasound (B/M scan mode Signos U/S scanner, Signostics Inc., Palo Alto, CA, USA). After Ad.CD instillation the catheter was flushed with 25 cc of sterile normal saline and capped for 12 hours. The patients were also asked to change body position to enable effective diffusion of the drug solution throughout the visceral and mural pleural. The radiographic response assessment was performed according to the RECIST (Response Evaluation Criteria In Solid Tumors) criteria. 34 This study was conducted in accordance with the ICH Harmonized Tripartite Good Clinical Practice Guidelines issued by the International Conference on Harmonization and the principles of the Declaration of Helsinki. 35 Furthermore, the study protocol was approved by the Investiga- À2 day À1 (D1--3). After the third cycle, he developed a left-sided hydropneumothorax. The fluid was drained by intercostal tube, but relapsed quickly and was cytology positive for SCLC. The patient was reluctant to have further systemic chemotherapy, but consented to the addition of experimental local gene therapy to the above systemic chemotherapy. Ad.CD was instilled into the pleura (total amount of 10 12 pfu given in two doses, 1-week apart, when daily effusion production was o150 ml) and the patient was also given orally 5-FC (Ancotil) 500 mg a day before Ad.CD infusion and for the next 13 days four times daily (qds).
Case-2. A 68-year-old man presented with infiltration of the right upper lobe and ipsilateral protrachea, paratrachea and hilar lymphadenopathy. Investigation disclosed a stage IIIb adenocarcinoma of the lung. He received two cycles of chemotherapy with docetaxel 75 mg m À2 and cardoplatin AUC ¼ 5.5 (D1). During the second month from the initial day of chemotherapy, he developed a right-sided MPE cytologically positive for lung adenocarcinoma. The fluid relapsed quickly despite chest tube intubation for 13 days. The pleural fluid was drained through intercostal tube, and the treatment procedure was performed when the daily fluid production was o200 ml. We chose to reinforce the initial doublet chemotherapy, with the addition of 5-FU (as local gene therapy). Intrapleural Ad.CD (total amount of 10 12 pfu in two doses, 1-week apart) was instilled followed by the above described systemic chemotherapy. The patient also received Ancotil 500 mg qds 1 a day before AdCD instillation and for the next 13 days as previously.
RESULTS
Lewis mouse model
Tumor volumes observed were smaller in Group C receiving Ad.CD and 5-FC, tumor volume was smaller compared with Groups A and B. Indeed, tumor volumes upon death were: Group A 2308.5 (2035--2459) mm 3 , Group B 1050.5 (902--1345) mm 3 and for Group C 346.5 (266--478) mm 3 . Cox-regression analysis demonstrated P ¼ 0.008 for tumor volume to survival (all animals); for group A ¼ 0.002, for group B ¼ 0.009 and for group C ¼ 0.02. Significant survival benefit between the Group A as compared with Groups B P ¼ 0.014 and C Po ¼ 0.03. Breslow (Generalized Wilcoxon) test. (Figures 5 and 6 ).
In total, 27 mice had died before the 28th day: 12 from Group A, 9 from Group B and 6 from Group C. Lewis mouse lung carcinoma 
observation with electromicroscopy demonstrated that the cells were infected with the adenovirus particles. (Figure 2 ) Effectiveness of the combination treatment was prominent in the adenovirus infected cells as fragmentation of the nuclear chromatins was observed after 5-FC administration. (Figure 3) .
Human model
Case-1. Within 2 weeks of treatment re-accumulation of the fluid stopped and the drain was removed. On follow-up, there was no evidence of pleural effusion (Figure 7) . The main hematological toxicity was grade 3 neutrapenia. Flu-like adenoviral vector-related fever (37.5 1C) was observed only during the first instillation for 3 days. The fever was managed with the administration of acetaminophane, during the fever spikes. The patient's disease relapsed in the mediastinum 14 months after the intrapleural instillation. He underwent second-line chemotherapy, but died 18 months after the gene therapy initiation, because of disease progression, without re-accumulation of the pleural fluid. In the MPE, adenoviral vector particles were observed with electromicroscopy, 24 h after the first instillation. (Figure 4) Case-2. The MPE production stopped on the eleventh day, 4 days after the second Ad.CD instillation and the chest tube was removed. Flu-like adenoviral vector-related fever (38 1C) was observed only after the first instillation and lasted for 5 days. The fever was managed with the administration of acetaminophane, during the fever spikes. Although, there was no pleural fluid re-accumulation, the patient died 3 months later because of disease progression. The patient experienced grade 4 neutrapenia and grade 3 anemia on the sixth and fourteenth day after Ad.CD administration, respectively.
DISCUSSION
One factor limiting the success of chemotherapy is the damage it causes to normal tissues. A second problem is the difficulty in delivering chemotherapy to cancer tissues directly. Gene therapy is considered a novel treatment and can be applied regionally. Two general approaches are under development. The first is to provide a therapeutic gene using an appropriate delivery vehicle. The therapeutic gene is a suppressor oncogene that may be inserted into tumor cells and restore suppressor functions, thus arresting uncontrolled cell proliferation. In the second approach, a variety of cell types can be genetically manipulated to augment the efficacy of chemotherapy and/or immunotherapy. In addition, hematopoietic stem cells might be modified with drug resistance genes to allow higher doses of chemotherapy to be given with less bone marrow toxicity. In general, the success of all these strategies depends on the technical ability of the delivery vehicle to efficiently insert genes into the eukaryotic cells. The adenoviral vectors are attractive for the delivery of chemotherapy sensitization genes to the tumor cells because they exhibit a tropism for epithelial cells, and they express their transgenes without integration into the chromosomal DNA of replicating cells. This makes them suitable for sensitization of slow-growing epithelial tumor cells from the colon, breast, prostate, ovary and lung. A number of different suicide gene therapy systems of delivery vectors and pro-drugs are under investigation in lung cancer and other types of cancer. 28--31,36,37 They all have advantages and disadvantages, and so far there is no ideal vehicle.
The herpes simplex virus thymidine kinase (HSV-tk) gene has been the most extensively studied suicide gene so far. This system involves the use of the HSV-tk to activate the antiviral agent ganciclovir so that it is toxic for mammalian cells. 38, 39 This strategy is based on the conversion of ganciclovir to the active monophosphate form, with subsequent formation of the triphoshate by other cellular enzymes. The phosphorylated derivative inactivates the DNA polymerase by competitive inhibition and after its incorporation prevents DNA elongation. HSV-tk vectors have been able to selectively kill liver metastases, brain tumors, lung cancer cells, hepatocellular carcinomas and lymphomas after transduction following systemic administration of ganciclovir. 38, 39 In the CD/5-FC suicide gene therapy system studied here, the CD transcription unit in the adenoviral vector catalyses the deamination of the non-toxic pro-drug 5-FC, thus converting it to the cytotoxic drug 5-FU. This adenoviral vector pro-drug activation system has been proposed for use in selectively sensitizing lung cancer cells, which may contaminate collections of autologous stem cell products from lung cancer patients, to the toxic effects of 5-FC; however, without damaging the reconstitutive capability of the normal hematopoietic cells. In suicide gene therapy applications, the gene for CD is delivered to cancer cells and the individual is subsequently treated systematically with the non-toxic 5-FC prodrug. The CD from E. Coli (Ad.CD) has been used successfully for a variety of animal tumor models and is under investigation for the treatment of human cancers. 19--21,23,40,41 The Ad.CD/5-FC system also relies on the 'bystander effect' for tumor ablation; however, this system displays the advantage that the pro-drug product is freely diffusible across cell membranes, allowing localized general toxicity independent of the gap junctions or active transport in the tumor bed. 22--31 Our results demonstrating positive tumor control in the Lewis mouse lung cancer model provided evidence for successful adenoviral infection of cancer cells and tumor regression, indicating that this approach could be further pursued in human subjects. Similar protocols using this technique with or without concurrent chemotherapy have been reported in previous in vivo studies. 40,42--45 In the presented two cases, MPE was diagnosed during the first-line chemotherapy, with cytology positive effusion. Alternative treatment of MPE has been presented in previous studies with various results and techniques. 10, 11, 44 Here, we present results of regionally applied suicide gene therapy augmenting the chemotherapy effect in these two patients who were successfully treated. A secondary treatment pathway may involve the diffusion of the 5-FU cytotoxic metabolite through the pleura porous to the lymphatic circulation 46, 47 , as it has been previously observed that different concentrations of administered drug formulations enter the lymphatic circulation through the pleura porous. 48 Gene therapy studies in advance stage lung cancer patients with MPE treated with intracostal instillation of adenovirus have presented promising results. In a Phase I trial by Sterman et al. (2007) 43 , effectiveness and safety of the Ad. IFN-b was investigated firstly in animals and then in 10 patients with MPE (8 mesolthelioma, 1 NSCLC and 1 ovarian). The rAd-IFN-b was administered at doses raging from 9 Â 10 11 to 3 Â 10 12 pfu. The major adverse effect recorded was liver function abnormality and hypoxia (at doses of 3 Â 10 12 pfu). The second was attributed to congestive heart failure and was resolved with diuretics. High levels of cytokines were recorded after gene transfer. Antitumor immune response was observed in 7 out 10 patients. It was demonstrated, that a single dose of Ad. IFN-b was enough to present 18 FDG-PET response and prolong disease stability. In a second phase I trial by Sterman et al.
(2010) 44 , it was investigated whether the administration of Ad. IFN-b twice (with 7 days and 14 days intervals) would be more beneficial for the patients with MPE. The ranges of doses evaluated were again between 1 Â 10 12 to 3 Â 10 12 pfu in 17 patients (3 lung cancer, 10 mesothelioma, 2 breast cancer and 2 ovarian cancers). The major adverse effect was pericardial pleural effusion accumulation in one patient, and it was attributed to adenoviral inflammatory response. Other minor adverse effects were anemia, lymphopenia, flu-like symptom, hypotension and hypoalbuminemia. It was concluded that administering twice the treatment was not as effective as anticipated, owing to the antibodies that tend to form after the first instillation, with less antibodies formed in the 7 days interval group. In specific, it was investigated by administering the Ad. IFN-b with 7 days and 14 days intervals. It was observed that fewer antibodies were formed in the 7 days interval group. Therefore, the authors proposed as a future direction to administer a second dose after 3 days. In a study by Dong et al. ) intracavitary plus rAD-p53 (1 Â 10 12 VP). Additional dexamethasone (10 mg) was administered intravenously to reduce adverse effects. Fever was the major adverse effect observed, but it was self-limited and recovered after 36 h. It was attributed to the adenovirus instillation and it was proposed that administering orally apamide 30 min before the instillation could alleviate the fever. The treatment was administered for 4 weeks. (Table 1) .
Moreover, the presented data demonstrate that gene therapy treatment could also be applied to malignant pleural mesothelioma. 43, 45, 50, 51 It has been previously investigated that chondroitin sulfates and proteoglycans/glycosaminoglycans that exist within the pleural effusion interact with the vector in the solution and not with the target cells and therefore inhibit the treatment. 52, 53 Although, an enzymatic pre-treatment was proposed, further investigation of the molecular pathways of MPE discouraged this approach. 53 In specific, it was observed that even with enzymatic pre-treatment, the binding of the Ad was still inhibited by the MPE. Strategies to overcome this inhibition were proposed: (a) targeting the airway epithelium 54 , (b) pre-treatment with corticosteroids, 55 (c) alternate serotypes, 56 (d) coutilization of immunomodulatory or cytotoxic therapy 57, 58 and (e) the construction of Ad vectors, which extend the longevity of transduced cells in immunocompetent hosts. 59, 60 Furthermore, the lack of expression of the adenovirus is correlated with the rapid induction of neutralizing Ad antibodies (Nabs). It is a fact that anti-Ad antibodies are highly prevalent in the human population, depending on geographical region and the detection method. 61 In addition, to achieve sufficient therapeutic effects, administration of high doses of Ad vectors is needed, which causes side-effects 62 and is indeed associated with increased toxicity. 63 Several efforts have been made towards diminishing the immune response. These strategies include modification of viral capsids, 64 covalent conjugation of polyethleneglycol to Ad vectors, 65--68 hydrodynamic injections toward local delivery of low-vector doses directly into the liver, 69 pretreatment with gulucocortocoid, use of lipid bilayer envelopes and preventing binding to the CAR (coxsackie B and adenovirus receptor) receptor by masking the adenoviral fiber knob. 70--72 However, recent data suggest that combination of immunotherapy with chemotherapy can overcome the inability to give multiple doses, resulting the boosting of the initial vaccination of the adenovirus. 44, 73 This approach is currently being tested in a clinical trial using Ad.IFN in combination with cisplatin/gemcitabine and cisplatin/ pemetrexed in patients with mesothelioma and could be applied to other trials of viral immunogene therapy. 73 Following our first favourable observations of suicide gene therapy in the presented two cases of MPE secondary to lung cancer, we propose a protocol for local control of MPE.
Firstly, we present the inclusion criteria for possible candidates for such a strategy, and secondly, propose an algorithm of treatment ( Table 2 ). The most important inclusion criteria should be: (a) MPE secondary to lung cancer (proven pathologically or cytological) resisted to conventional treatment, (b) age up to 70 years, (c) expected survival more than X3months and (d) performance status 0--1.
All adverse events will be recorded. A patient will exit the protocol if MPE is regenerated. Moreover, after the second instillation, the detection for vector antibodies is recommended, as previous studies have demonstrated that antibodies are formed usually between the second and third administration. 43, 44, 74 In conclusion, the increased toxicity that follows the intrapleural gene therapy indicates the augmentation of anticancer effect of transformed pro-drug 5-FC to active 5-FU with Ad.CD. Intrapleural gene therapy may be a useful adjunct to chemotherapy in the management of MPE related to lung cancer in patients with good performance status. 
